Vaccines for young children are being delayed by incomplete data, a top F.D.A. official suggests.news2022-04-26T23:00:56+00:00April 26th, 2022|The New York Times|
Congress Has to Ask How Much McKinsey Hurt the F.D.A.news2022-04-26T18:56:24+00:00April 26th, 2022|The New York Times|
Pfizer Says Booster Strengthens Immune Response for Children 5 to 11news2022-04-14T22:14:31+00:00April 14th, 2022|The New York Times|
McKinsey Opened a Door in Its Firewall Between Pharma Clients and Regulatorsnews2022-04-13T22:06:06+00:00April 13th, 2022|The New York Times|
New Drug Slashed Deaths Among Patients With Severe Covid, Maker Claimsnews2022-04-11T21:52:16+00:00April 11th, 2022|The New York Times|
Medicare Officially Limits Coverage of Aduhelm to Patients in Clinical Trialsnews2022-04-07T23:32:59+00:00April 7th, 2022|The New York Times|
The F.D.A. Suspends Use of Glaxo Antibody Drug in the U.S.news2022-04-05T22:36:24+00:00April 5th, 2022|The New York Times|
F.D.A. Allows Second Coronavirus Boosters for Everyone 50 and Oldernews2022-03-29T23:44:53+00:00March 29th, 2022|The New York Times|
Biden Administration Plans to Offer Second Booster Shots to Those 50 and Upnews2022-03-26T14:29:54+00:00March 26th, 2022|The New York Times|
F.D.A. Rushed a Drug for Preterm Births. Did It Put Speed Over Science?news2022-03-25T15:15:07+00:00March 25th, 2022|The New York Times|
